Statins in heart failure: do we need another trial?

References

• McMurrayJJAdamopoulosSAnkerSDESC Committee for Practice GuidelinesESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEur J Heart Fail201214880386922828712
   PubMed Web of Science ®Google Scholar
• WierzbickiASPostonRFerroAThe lipid and non-lipid effects of statinsPharmacol Ther20039919511212804701
   PubMed Web of Science ®Google Scholar
• SchachterMChemical, pharmacokinetic and pharmacodynamic properties of statins: an updateFundam Clin Pharmacol200519111712515660968
   PubMed Web of Science ®Google Scholar
• Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet19943448934138313897968073
   PubMed Web of Science ®Google Scholar
• ShepherdJCobbeSMFordIPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study GroupN Engl J Med199533320130113077566020
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study GroupN Engl J Med199833919134913579841303
   PubMed Web of Science ®Google Scholar
• LaufsUKilterHKonkolCWassmannSBöhmMNickenigGImpact of HMG CoA reductase inhibition on small GTPases in the heartCardiovasc Res200253491192011922901
   PubMed Web of Science ®Google Scholar
• LaufsULiaoJKPost-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPaseJ Biol Chem19982733724266242719727051
   PubMed Web of Science ®Google Scholar
• LaufsULiaoJKIsoprenoid metabolism and the pleotropic effects of statinsCurr Atheroscler Rep20035537237812911847
   PubMedGoogle Scholar
• SacksFMPfefferMAMoyeLAThe effect of pravastatin on coronary events after myocardial myocardial infarction in patients with average cholesterol levels.Cholesterol and Recurrent Events trial investigatorsN Engl J Med199633514100110098801446
   PubMed Web of Science ®Google Scholar
• SchwartzGGOlssonAGEzekowitzMDMyocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study InvestigatorsEffects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomised controlled trialJAMA2001285131711171811277825
   PubMed Web of Science ®Google Scholar
• de LemosJABlazingMAWiviottSDInvestigatorsEarly intensive versus a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trialJAMA2004292111307131615337732
   PubMed Web of Science ®Google Scholar
• KorenMJHunninghakeDBALLIANCE InvestigatorsClinical outcomes in managed care patients with coronary heart diseas treated agressively in lipid-lowering disease management clinics: the alliance studyJ Am Coll Cardiol20044491772177915519006
   PubMed Web of Science ®Google Scholar
• EzekowitzJMcAlisterFAHumphriesKHAPPROACH InvestigatorsThe association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery diseaseJ Am Coll Cardiol20044481587159215489090
   PubMed Web of Science ®Google Scholar
• KjekshusJApetreiEBarriosVCORONA GroupRosuvastatin in older patients with systolic heart failureN Engl J Med2007357222248226117984166
   PubMed Web of Science ®Google Scholar
• TavazziLMaggioniAPMarchioliRGissi-HF InvestigatorsEffect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialLancet200837296451231123918757089
   PubMed Web of Science ®Google Scholar
• RauchhausMCoatsAJAnkerSDThe endotoxin-lipoprotein hypothesisLancet2000356923393093311036910
   PubMed Web of Science ®Google Scholar
• RamasubbuKEstepJWhiteDLDeswalAMannDLExperimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathyJ Am Coll Cardiol200851441542618222351
   PubMed Web of Science ®Google Scholar
• van der HarstPVoorsAAvan GilstWHBöhmMvan VeldhuisenDStatins in the treatment of chronic heart failure: a systematic reviewPLoS Med200638e33316933967
   PubMed Web of Science ®Google Scholar
• FurchgottRFZawadzkiJVThe obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholineNature198028857893733766253831
   PubMed Web of Science ®Google Scholar
• RubanyiGMRomeroJCVanhouttePMFlow-induced release of endothelium-derived relaxing factorAm J Physiol19862506 Pt 2H1145H11493487253
   PubMed Web of Science ®Google Scholar
• LibbyPAikawaMJainMKVascular endothelium and atherosclerosisHandb Exp Pharmacol2006176 Pt 228530616999230
   PubMedGoogle Scholar
• DavignonJGanzPRole of endothelial dysfunction in atherosclerosisCirculation200410923 Suppl 1III27III3215198963
   PubMed Web of Science ®Google Scholar
• BauersachsJWidderJDEndothelial dysfunction in heart failurePharmacol Rep200860111912618276993
   PubMed Web of Science ®Google Scholar
• RamseyMWGoodfellowJJonesCJLuddingtonLALewisMJHendersonAHEndothelial control of arterial distensibility is impaired in chronic heart failureCirculation19959211321232197586306
   PubMed Web of Science ®Google Scholar
• BuusNHBøttcherMHermansenFSanderMNielsenTTMulvanyMJInfluence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemiaCirculation2001104192305231011696470
   PubMed Web of Science ®Google Scholar
• Vásquez-VivarJKalyanaramanBMartásekPSuperoxide generation by endothelial nitric oxide synthase: the influence of cofactorsProc Natl Acad Sci USA19989516922092259689061
   PubMed Web of Science ®Google Scholar
• BorlaugBAMelenovskyVRussellSDImpaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fractionCirculation2006114202138214717088459
   PubMed Web of Science ®Google Scholar
• LaufsULa FataVPlutzkyJLiaoJKUpregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitorsCirculation19989712112911359537338
   PubMed Web of Science ®Google Scholar
• von HaehlingSAnkerSDBassengeEStatins and the role of nitric oxide in chronic heart failureHeart Fail Rev2003819910612652163
   PubMed Web of Science ®Google Scholar
• VaughanCJMurphyMBBuckleyBMStatins do more than just lower cholesterolLancet19963489034107910828874463
   PubMed Web of Science ®Google Scholar
• Hernández-PereraOPérez-SalaDNavarro-AntolínJEffects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cellsJ Clin Invest199810112271127199637705
   PubMed Web of Science ®Google Scholar
• KatzSKhanTZeballosGADecreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failureCirculation199999162113211710217650
   PubMed Web of Science ®Google Scholar
• DattaSR BAGreenbergMECellular survival: a play in three AktsGenes Dev199913222905292710579998
   PubMed Web of Science ®Google Scholar
• KureishiYLuoZShiojimaIThe HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animalsNat Med2000691004101010973320
   PubMed Web of Science ®Google Scholar
• WilliamsJKSukhovaGKHerringtonDMLibbyPPravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeysJ Am Coll Cardiol19983136846919502654
   PubMed Web of Science ®Google Scholar
• JonesSPGreerJJvan HaperenRDunckerDJde CromRLeferDJEndothelial nitric oxide synthase overexpression attenuates congestive heart failure in miceProc Natl Acad Sci USA200310084891489612676984
   PubMed Web of Science ®Google Scholar
• AmudhaKChoyAMMustafaMRLangCCShort-term effect of atorvastatin on endothelial function in healthy offspring of parents with type 2 diabetes mellitusCardiovasc Ther200826425326119035876
   PubMed Web of Science ®Google Scholar
• EgashiraKHirookaYKaiHReduction in serum cholesterol with pravastatin improves endothelium dependent coronary vasomotion in patients with hypercholesterolemiaCirculation1994896251925248205659
   PubMed Web of Science ®Google Scholar
• StroesESKoomansHAde BruinTWRabelinkTJVascular function in the forearm of hypercholesterolaemic patient’s off and on lipid-lowering medicationLancet199534689734674717637480
   PubMed Web of Science ®Google Scholar
• LevineBKalmanJMayerLFillitHMPackerMElevated circulating levels of tumor necrosis factor in severe chronic heart failureN Engl J Med199032342362412195340
   PubMed Web of Science ®Google Scholar
• PackerMIs tumor necrosis factor an important neurohormonal mechanism in chronic heart failure?Circulation1995926137913827664414
   PubMed Web of Science ®Google Scholar
• PinskyDJCaiBYangXRodriguezCSciaccaRRCannonPJThe lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor betaJ Clin Invest19959526776857532189
   PubMed Web of Science ®Google Scholar
• PahanKSheikhFGNamboodiriAMSinghILovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophagesJ Clin Invest199710011267126799389730
   PubMed Web of Science ®Google Scholar
• RosensonRSTangneyCCCaseyLCInhibition of proinflammatory cytokine production by pravastatinLancet1999353915798398410459915
   PubMed Web of Science ®Google Scholar
• GripOJanciauskieneSLindgrenSPravastatin down-regulates inflammatory mediators in human monocytes in vitroEur J Pharmacol20004101839211134659
   PubMed Web of Science ®Google Scholar
• GoldsteinJLBrownMSRegulation of the mevalonate pathwayNature199034362574254301967820
   PubMed Web of Science ®Google Scholar
• CaseyPJProtein lipidation in cell signalingScience199526852082212257716512
   PubMed Web of Science ®Google Scholar
• DechendRFiebelerAParkJKAmelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitorCirculation2001104557658111479256
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFAJUPITER Study GroupRosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN Engl J Med2008359212195220718997196
   PubMed Web of Science ®Google Scholar
• ThomasCVCokerMLZellnerJLHandyJRCrumbleyAJ3rdSpinaleFGIncreased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathyCirculation19989717170817159591765
   PubMed Web of Science ®Google Scholar
• BellostaSViaDCanavesiMHMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophagesArterioscler Thromb Vasc Biol19981811167116789812903
   PubMed Web of Science ®Google Scholar
• AikawaMRabkinESugiyamaSAn HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitroCirculation2001103227628311208689
   PubMed Web of Science ®Google Scholar
• ClelandJGMcMurrayJJKjekshusJCORONA Study GroupPlasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)J Am Coll Cardiol200954201850185919892235
   PubMed Web of Science ®Google Scholar
• KangPMIzumoSApoptosis and heart failure: A critical review of the literatureCirc Res200086111107111310850960
   PubMed Web of Science ®Google Scholar
• ThunyakitpisalPDChaisuparatRSimvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cellsJournal of Pharmacological Sciences200494440340915107580
   PubMed Web of Science ®Google Scholar
• MitaniHBandohTIshikawaJKimuraMTotsukaTHayashiSInhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbitsBr J Pharmacol19961196126912758937733
   PubMed Web of Science ®Google Scholar
• LuoJDZhangWWZhangGPGuanJXChenXSimvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosisClin Exp Pharmacol Physiol1999261190390810561812
   PubMed Web of Science ®Google Scholar
• TakemotoMNodeKNakagamiHStatins as antioxidant therapy for preventing cardiac myocyte hypertrophyJ Clin Invest2001108101429143711714734
   PubMed Web of Science ®Google Scholar
• ShepherdJBlauwGJMurphyMBPROSPER study groupPROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialLancet200236093461623163012457784
   PubMed Web of Science ®Google Scholar
• KrumHAshtonEReidCDouble-Blind, randomized, placebo-controlled study of high-dose hmg coa reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failureJ Card Fail20071311717338996
   PubMed Web of Science ®Google Scholar
• CannonCPBraunwaldEMcCabeCHPravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 InvestigatorsIntensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med2004350151495150415007110
   PubMed Web of Science ®Google Scholar
• SharmaUCPokharelSvan BrakelTJGalectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunctionCirculation2004110193121312815520318
   PubMed Web of Science ®Google Scholar
• van KimmenadeRRJanuzziJLJrEllinorPTUtility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failureJ Am Coll Cardiol20064861217122416979009
   PubMed Web of Science ®Google Scholar
• LokDJVan Der MeerPde la PortePWPrognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF studyClin Res Cardiol201099532332820130888
   PubMed Web of Science ®Google Scholar
• de BoerRALokDJJaarsmaTPredictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fractionAnn Med2011431606821189092
   PubMed Web of Science ®Google Scholar
• GullestadLUelandTKjekshusJCORONA Study GroupGalectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)Eur Heart J201233182290229622513778
   PubMed Web of Science ®Google Scholar
• van der HarstPVoorsAAvan GilstWHvan VeldhuisenDJStatins and autonomic function in chronic heart failureCardiovasc Drugs Ther200519316716816142591
   PubMed Web of Science ®Google Scholar
• GoldmanSJohnsonGCohnJNCintronGSmithRFrancisGMechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies GroupCirculation199387Suppl 6VI24VI318500236
   PubMed Web of Science ®Google Scholar
• MudersFKromerEPGrieseDPEvaluation of plasma natriuretic peptides as markers for left ventricular dysfunctionAm Heart J199713434424499327700
   PubMed Web of Science ®Google Scholar
• RidkerPMRifaiNPfefferMASacksFBraunwaldELong-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) InvestigatorsCirculation1999100323023510411845
   PubMed Web of Science ®Google Scholar
• OiSHanedaTOsakiJLovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cellsEur J Pharmacol19993761–213914810440099
   PubMed Web of Science ®Google Scholar
• PliquettRUCornishKGPeulerJDZuckerIHSimvastatin normalizes autonomic neural control in experimental heart failureCirculation2003107192493249812695293
   PubMed Web of Science ®Google Scholar
• MassonSLatiniRAnandISVal-HeFT InvestigatorsDirect comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) dataClin Chem20065281528153816777915
   PubMed Web of Science ®Google Scholar
• OmlandTSabatineMSJablonskiKAPEACE InvestigatorsPrognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE TrialJ Am Coll Cardiol200750320521417631211
   PubMed Web of Science ®Google Scholar
• TulevskiIIGroeninkMvan Der WallEEIncreased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunctionHeart2001861273011410557
   PubMed Web of Science ®Google Scholar
• KrügerSGrafJKunzDStickelTHanrathPJanssensUBrain natriuretic peptide levels predict functional capacity in patients with chronic heart failureJ Am Coll Cardiol200240471872212204502
   PubMed Web of Science ®Google Scholar
• McDonaghTARobbSDMurdochDRBiochemical detection of left-ventricular systolic dysfunctionLancet199835190959139433422
   PubMed Web of Science ®Google Scholar
• NakayaRUzuiHShimizuHPravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarctionInt J Cardiol20051051677316207547
   PubMed Web of Science ®Google Scholar
• HayashidaniSTsutsuiHShiomiTFluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarctionCirculation2002105786887311854129
   PubMed Web of Science ®Google Scholar
• KeidarSAviramMMaorIOiknineJBrookJGPravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studiesBr J Clin Pharmacol19943865135197888289
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trialLancet2002360932672212114036
   PubMed Web of Science ®Google Scholar
• RemmeWJOverview of the relationship between ischemia and congestive heart failureClin Cardiol2000237 Suppl 4IV4IV810894449
   PubMed Web of Science ®Google Scholar
• RosensonRSTangneyCCAntiatherothrombotic properties of statins: implications for cardiovascular event reductionJAMA199827920164316509613915
   PubMed Web of Science ®Google Scholar
• KjekshusJPedersenTROlssonAGFaergemanOPyöräläKThe effects of simvastatin on the incidence of heart failure in patients with coronary heart diseaseJ Card Fail1997342492549547437
   PubMedGoogle Scholar
• JacksonGGibbsCRDaviesMKLipGYABC of heart failure. PathophysiologyBMJ2000320722816717010634740
   PubMedGoogle Scholar
• HannaIRHeekeBBushHLipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunctionHeart Rhythm20063888188616876733
   PubMed Web of Science ®Google Scholar
• FauchierLPierreBde LabriolleAGrimardCZannadNBabutyDAntiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trialsJ Am Coll Cardiol200851882883518294568
   PubMed Web of Science ®Google Scholar
• VyasAKGuoHMossAJMADIT-II Research GroupReduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-IIJ Am Coll Cardiol200647476977316487843
   PubMed Web of Science ®Google Scholar
• GoldbergerJJSubaciusHSchaechterADEFINITE InvestigatorsEffects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathyJ Am Coll Cardiol20064861228123316979011
   PubMed Web of Science ®Google Scholar
• TamargoJCaballeroRGómezRNúñezLVaqueroMDelpónELipid-lowering therapy with statins, a new approach to antiarrhythmic therapyPharmacol Ther2007114110712617287023
   PubMed Web of Science ®Google Scholar
• AdamOFrostGCustodisFRole of Rac1 GTPase activation in atrial fibrillationJ Am Coll Cardiol200750435936717659204
   PubMed Web of Science ®Google Scholar
• RahimiKEmbersonJMcGalePPROSPER ExecutiveEffect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trialsBMJ2011342d125021411487
   PubMedGoogle Scholar
• RauchhausMClarkALDoehnerWThe relationship between cholesterol and survival in patients with chronic heart failureJ Am Coll Cardiol200342111933194014662255
   PubMed Web of Science ®Google Scholar
• TreasureCBKleinJLWeintraubWSBeneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery diseaseN Engl J Med199533284814877830728
   PubMed Web of Science ®Google Scholar
• MortensenSALethAAgnerERohdeMDose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitorsMol Aspects Med199718SupplS137S1449266515
   PubMedGoogle Scholar
• MoosmannBBehlCSelenoprotein synthesis and side-effects of statinsLancet2004363941289289415031036
   PubMed Web of Science ®Google Scholar
• PoehlmanETScheffersJGottliebSSFisherMLVaitekeviciusPIncreased resting metabolic rate in patients with congestive heart failureAnn Intern Med1994121118608627772113
   PubMed Web of Science ®Google Scholar
• RundekTNainiASaccoRCoatesKDiMauroSAtorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and strokeArch Neurol200461688989215210526
   PubMedGoogle Scholar
• AthyrosVGMikhailidisDPPapageorgiouAAEffect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) StudyCurrent medical research and opinion5200420562763715171226
   PubMed Web of Science ®Google Scholar
• PedersenTRFaergemanOKasteleinJJIncremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study GroupHigh – dose atorvastatin vrs usual – dose simvastatin for secondary prevention after myocardial infarction: IDEAL study: a randomized-controlled trialJAMA2005294192437244516287954
   PubMed Web of Science ®Google Scholar
• KhushKKWatersDDBittnerVEffect of high-dose atorvastatin on hospitalization for heart failure: subgroup analysis of the Treat to New Targets (TNT) studyCirculation2007115557658317261662
   PubMed Web of Science ®Google Scholar
• KubotaTMiyagishimaMAlvarezRJExpression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failureJ Heart Lung Transplant200019981982411008069
   PubMed Web of Science ®Google Scholar
• KrumHLatiniRMaggioniAPStatins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFTInt J Cardiol20071191485317049646
   PubMed Web of Science ®Google Scholar
• KrumHBaileyMMeyerWImpact of statin therapy on mortality in CHF patients according to beta-blocker use: results of CIBIS IICardiology20071081283416960445
   PubMed Web of Science ®Google Scholar
• AnkerSDClarkALWinklerRStatin use and survival in patients with chronic heart failure: results from two observational studies with 5200 patientsInt J Cardiol2006112223424216846656
   PubMed Web of Science ®Google Scholar
• JoyntKEGattisWAHasselbladVEffect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failureAm J Cardiol200493678378515019895
   PubMed Web of Science ®Google Scholar
• GoASLeeWYYangJLoJCGurwitzJHStatin therapy and risks for death and hospitalization in chronic heart failureJAMA2006296172105211117077375
   PubMed Web of Science ®Google Scholar
• FoodyJMShahRGalushaDMasoudiFAHavranekEPKrumholzHMStatin and mortality among elderly patients hospitalized with heart failureCirculation200611381086109216490817
   PubMed Web of Science ®Google Scholar
• HognestadADicksteinKMyhreESnapinnSKjekshusJOPTIMAAL InvestigatorsEffect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failureAm J Cardiol200493560360614996587
   PubMed Web of Science ®Google Scholar
• RayJGGongYSykoraKTuJVStatin use and survival outcomes in elderly patients with heart failureArch Intern Med20051651626715642876
   PubMedGoogle Scholar
• SolaSMirMQSRajagopalanSHelmyTTandonNKhanBVStatin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failureJ Card Fail200511860761216230264
   PubMed Web of Science ®Google Scholar
• ThambidoraiSKDeshmukhARWaltersRWImpact of statin use on heart failure mortalityInt J Cardiol2011147343844320971517
   PubMed Web of Science ®Google Scholar
• MaisonPDesamericqGHemeryFRelationship between recommended chronic heart failure treatments and mortality over 8 years in real-world conditions: a pharmacoepidemiological studyEur J Clin Pharmacol201369490190822993100
   PubMed Web of Science ®Google Scholar
• GastelurrutiaPLupónJde AntonioMStatins in heart failure: the paradox between large randomized clinical trials and real lifeMayo Clin Proc201287655556022677075
   PubMed Web of Science ®Google Scholar
• VrtovecBOkrajsekRGolicnikAAtorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failureJ Card Fail200814214014418325461
   PubMed Web of Science ®Google Scholar
• WojniczRWilczekKNowalany-KozielskaEUsefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levelsAm J Cardiol200697689990416516598
   PubMed Web of Science ®Google Scholar
• XieRQCuiWLiuFYangCPeiWNLuJCStatin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failureInt J Cardiol2010140225525719042044
   PubMed Web of Science ®Google Scholar
• SolaSMirMQLerakisSTandonNKhanBVAtorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failureJ Am Coll Cardiol200647233233716412856
   PubMed Web of Science ®Google Scholar
• YamadaTNodeKMineTLong-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: A prospective randomized controlled studyAm Heart J200715361055. e11055. e817540209
   PubMed Web of Science ®Google Scholar
• NodeKFujitaMKitakazeMHoriMLiaoJKShort-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathyCirculation2003108783984312885745
   PubMed Web of Science ®Google Scholar
• HamaadASosinMLipGYMacFadyenRJShort-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failureCardiovasc Drugs Ther200519318318716142595
   PubMed Web of Science ®Google Scholar
• BleskeBENicklasJMBardRLNeutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein levelJ Am Coll Cardiol200647233834116412857
   PubMed Web of Science ®Google Scholar
• LaufsUWassmannSSchackmannSHeeschenCBöhmMNickenigGBeneficial effects of statins in patients with non-ischemic heart failureZ Kardiol200493210310814963675
   PubMedGoogle Scholar
• TousoulisDAndreouITentolourisCComparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failureInt J Cardiol2010145343844319539384
   PubMed Web of Science ®Google Scholar
• ErbsSBeckEBLinkeAHigh-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling – results from a randomized, double-blind, and placebo-controlled studyInt J Cardiol20111461566320236716
   PubMed Web of Science ®Google Scholar
• TsutamotoTSakaiHIbeKEffect of atorvastatin vs rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathyCirc J20117592160216621737951
   PubMed Web of Science ®Google Scholar
• AndreouITousoulisDMiliouAEffects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled studyAtherosclerosis2010210119419819962701
   PubMed Web of Science ®Google Scholar
• Bielecka-DabrowaAGochJHMikhailidisDPRyszJMaciejewskiMBanachMThe influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathyMed Sci Monit20091512MS12MS2319946241
   PubMed Web of Science ®Google Scholar
• TousoulisDAntoniadesCBosinakouEEffects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failureAtherosclerosis2005178235936315694946
   PubMed Web of Science ®Google Scholar
• HorwichTBMiddlekauffHRMaclellanWRFonarowGCStatins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trialJ Card Fail2011171187988622041323
   PubMed Web of Science ®Google Scholar
• ZhangSZhangLSunAJiangHQianJGeJEfficacy of statin therapy in chronic systolic cardiac insufficiency: a meta-analysisEur J Intern Med201122547848421925056
   PubMed Web of Science ®Google Scholar
• LipinskiMJCauthenCABiondi-ZoccaiGGMeta-analysis of randomized controlled trials of statins versus placebo in patients with heart failureAm J Cardiol2009104121708171619962481
   PubMed Web of Science ®Google Scholar
• EmbersonJRNgLLArmitageJBowmanLParishSCollinsRHeart Protection Study Collaborative GroupN-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection studyJ Am Coll Cardiol200749331131917239712
   PubMed Web of Science ®Google Scholar
• OchiaiMEBarrettoACOliveiraMTJrMunhozRTMorgadoPCRamiresJAUric acid renal excretion and renal insufficiency in decompensated severe heart failureEur J Heart Fail20057446847415921781
   PubMed Web of Science ®Google Scholar
• RinfretSBehlouliHEisenbergMJHumphriesKTuJVPiloteLClass effects of statins in elderly patients with congestive heart failure: a population-based analysisAm Heart J2008155231632318215603
   PubMed Web of Science ®Google Scholar
• JuncosLIJuncosLAGarcíaNHThe antihypertensive actions of statins: modulation by salt intakeAm J Hypertens201225111140114822833031
   PubMed Web of Science ®Google Scholar
• PelatMBalligandJLStatins and hypertensionSemin Vasc Med20044436737515861317
   PubMedGoogle Scholar
• LeyvaFAnkerSSwanJWSerum uric acid as an index of impaired oxidative metabolism in chronic heart failureEur Heart J19971858588659152657
   PubMed Web of Science ®Google Scholar
• AnkerSDDoehnerWRauchhausMUric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic stagingCirculation2003107151991199712707250
   PubMed Web of Science ®Google Scholar
• CengelATürkoğluSTurfanMBoyaciBSerum uric acid levels as a predictor of in-hospital death in patients hospitalized for decompensated heart failureActa Cardiol200560548949216261779
   PubMed Web of Science ®Google Scholar
• HareJMJohnsonRJUric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiologyCirculation2003107151951195312707249
   PubMed Web of Science ®Google Scholar
• MilionisHJKakafkaAITsouliSGEffects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemiaAm Heart J2004148463564015459594
   PubMed Web of Science ®Google Scholar
• AthyrosVGElisafMPapageorgiouAAGREACE Study Collaborative GroupEffect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) studyAm J Kidney Dis200443458959915042535
   PubMed Web of Science ®Google Scholar
• LjungmanSLaraghJHCodyRJRole of the kidney in congestive heart failure. Relationship of cardiac index to kidney functionDrugs199039Suppl 41021 discussion 22–24.1462354670
   PubMedGoogle Scholar
• ElisafMMikhailidisDPStatins and renal functionAngiology200253549350212365855
   PubMed Web of Science ®Google Scholar
• NagarajanVTangWHManagement of comorbid conditions in heart failure: a reviewMed Clin North Am201296597598522980059
   PubMed Web of Science ®Google Scholar
• De BloisJSimardSAtarDAgewallSNorwegian Heart Failure RegistryCOPD predicts mortality in HF: the Norwegian Heart Failure RegistryJ Card Fail201016322522920206897
   PubMed Web of Science ®Google Scholar
• SalpeterSROrmistonTMSalpeterEECardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysisChest200412562309232115189956
   PubMed Web of Science ®Google Scholar
• RocheNWhere current pharmacological therapies fall short in COPD: symptom control is not enoughEur Respir Rev20071610598104
   Google Scholar
• JandaSParkKFitzGeraldJMEtminanMSwistonJStatins in COPD: a systematic reviewChest2009136373474319376844
   PubMed Web of Science ®Google Scholar
• DoblerCCWongKKMarksGBAssociations between statins and COPD: a systematic reviewBMC Pulm Med200993219594891
   PubMedGoogle Scholar
• BonsuKOKadirveluAReidpathDDLipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysisSystematic reviews201322223618535
   PubMedGoogle Scholar